SCHEMBL3656124

SCHEMBL3656124

CC(C)CCNC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.74
LONP1 P36776 13/20 0.69
PSMB5 P28074 13/20 0.69
PSMB8 P28062 10/20 0.69
PSMB9 P28065 10/20 0.69
PSMB6 P28072 10/20 0.69
PSMB10 P40306 10/20 0.69
PSMB11 A5LHX3 9/20 0.69
PSMA7 O14818 9/20 0.69
PSMB1 P20618 9/20 0.69
PSMA1 P25786 9/20 0.69
PSMA2 P25787 9/20 0.69
PSMA3 P25788 9/20 0.69
PSMA4 P25789 9/20 0.69
PSMA5 P28066 9/20 0.69
PSMB4 P28070 9/20 0.69
PSMB3 P49720 9/20 0.69
PSMB2 P49721 9/20 0.69
PSMA6 P60900 9/20 0.69
PSMA8 Q8TAA3 9/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20093498 0.90 CTSL (0.78) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL20093501 0.87 CTSL (0.80) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL18543029 0.87 CTSL (0.80) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL21759114 0.85 CTSL (0.78) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL1913504 0.84 CTSL (0.61) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL18848799 0.84 PSMB5 (0.78) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL16492912 0.84 PSMB5 (0.78) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL21558117 0.84 PSMB5 (0.78) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL464470 0.84 PSMB5 (0.78) CTSLLONP1PSMB5PSMB8PSMB9
SCHEMBL16362648 0.84 PSMB5 (0.78) CTSLLONP1PSMB5PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170143622-A1 STABLE LIQUID READY-TO-USE INJECTABLE FORMULATION OF BORTEZOMIB Dr Reddys Laboratories Ltd (IN) 2017-05-25 US disclosed
US-20100092536-A1 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170143622-A1 STABLE LIQUID READY-TO-USE INJECTABLE FORMULATION OF BORTEZOMIB CUL5, CUL4B, CUL1 CTSL 1500/4885LONP1 2591/4885PSMB5 5/4885
US-20100092536-A1 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS MMP1, CDKN1A, MKI67 CTSL 1088/4885LONP1 1657/4885PSMB5 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.